Company Interview / Aces for EZZ as it serves up Aussie Open deal

Glenn Cross CEO of EZZ Life Science (ASX:EZZ) shares the details of its latest three-year sponsorship deal with the Australian Open to increase brand presence in China and South East Asia, aiming to reach a potential audience of 2 billion people. This partnership targets key markets including Australia and New Zealand.

Glenn highlights a growing middle class in China with an interest in health and well-being, making it a prime target for EZZ Life Science's (ASX:EZZ) product range. The deal is expected to drive consumer engagement, boost brand awareness, and enhance sales

EZZ Life Science (ASX:EZZ) has recently expanded into the US market with FDA approval for nine products. Their success is reflected in record revenue and a share price surge, leading to an ASX inquiry. Glenn asserts that their growth aligns with financial performance, ensuring strong market confidence.

Full unedited transcript below:

0:00

Health and anti-aging supplements. Easy Life Science has secured a three year sponsorship deal with the Australian Open. Beginning in 2025, to boost the brand's presence and exposure in China and South East Asia. To get across the details. Is it Chairman Glencross joining us now? Glenn, welcome back to Aussie. Thanks for joining us to tell us more. What this deal with the Australian Open tennis Championship means.

0:27

Well, I think it was a three year agreement as an official regional partner into China and South East Asia, um, which are currently our key markets along with Australia and New Zealand. I mean, there's 2 billion people in that marketplace. There's 330 million,

0:46

well, tennis players and tennis lovers, if you like, in China alone. Um, so it's very exciting for us. You know, for us it's about, um, driving consumer engagement. Um, boosting our brand awareness. Um, an exposure to new audience. And we trust increased sales. And what is it in your product range where you're targeting China in particular?

1:13

Yeah, the the market in China in particular. There's a growing middle class, uh, who, who now have money and they have, uh, an increased interest in their own personal health and well-being. And our products align exactly with that. So that's the market that we're chasing.

1:33

Uh, and beyond China, obviously, looking at Asia more broadly, what about global reach?

1:41

Well, the arrangement with Tennis Australia is, is a regional one. It's, uh, it's not a global, uh, a global reach. But in terms of, um, easyJet's business, where we've announced to the market recently that we're now, um, entering the US, uh, we've just had our first nine products approved by the FDA for sale and distribution in the USA. So that's our next exciting global global market.

2:07

And Glen, uh, looking at uh, your results from last month, uh, record revenue there, uh, you said you launched 21 new products, uh, gross margins above 75%. Your, uh, share price has rocketed. In fact, uh, you've been issued with a please explain from the ASX. Can you just detail, um, why that is? And have you responded? Yes, we we've responded to them. Um,

2:35

yeah. The share price has gone up significantly, but, uh, we believe our response to the ASX, uh, has covered all of the key issues they had. Um, I mean, essentially our growth over the last certainly the last two fiscal years has been very similar. So our growth in revenue, EBITDA, uh, and it's been mirrored by the increase in our, in our share price. But, um, we're very comfortable with, um, with our response back to the ASX.